search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

Mark Schuiveling ,
Laurens S Ter Maat ,
Isabella A J Van Duin ,
Rik J Verheijden ,
Max F Troenokarso ,
Pim Moeskops ,
Joost J C Verhoeff ,
Sjoerd G Elias ,
Wouter A C van Amsterdam ,
Femke Burgers ,
Franchette W P J Van den Berkmortel ,
Marye J Boers-Sonderen ,
Martijn F Boomsma ,
Jan Willem De Groot ,
John B A G Haanen ,
Geke A P Hospers ,
Djura Piersma ,
Gerard Vreugdenhil ,
Hans M Westgeest ,
Ellen Kapiteijn ,
Mariette Labots ,
Wouter B Veldhuis ,
Paul J Van Diest ,
Pim A De Jong ,
Josien P W Pluim ,
Tim Leiner ,
Mitko Veta ,
Karijn P M Suijkerbuijk

Abstract

METHODS

Patients treated with first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were retrospectively identified from 11 melanoma centers in The Netherlands. From baseline CT scans, 5 body composition metrics were extracted: subcutaneous adipose tissue index, visceral adipose tissue index, skeletal muscle index, density, and gauge. These metrics were correlated in univariable and multivariable Cox proportional hazards analysis with progression-free survival, overall survival, and melanoma-specific survival (PFS, OS, and MSS).

CONCLUSION

Our findings suggest that underweight BMI is associated with worse PFS, whereas higher skeletal muscle density and lower visceral adipose tissue index were associated with improved OS. These associations were independent of known prognostic factors, including sex, age, performance status, and extent of disease. No significant association between higher BMI and survival outcomes was observed.

RESULTS

A total of 1471 eligible patients were included. Median PFS and OS were 9.1 and 38.1 months, respectively. Worse PFS was observed in underweight patients (multivariable hazard ratio [HR] = 1.86, 95% CI = 1.14 to 3.06). Furthermore, prolonged OS was observed in patients with higher skeletal muscle density (multivariable HR = 0.88, 95% CI = 0.81 to 0.97) and gauge (multivariable HR = 0.61, 95% CI = 0.82 to 0.998), whereas higher visceral adipose tissue index was associated with worse OS (multivariable HR = 1.12, 95% CI = 1.04 to 1.22). No association with survival outcomes was found for overweight, obesity, or subcutaneous adipose tissue.

BACKGROUND

The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to investigate body mass index (BMI) alongside computed tomography (CT)-derived body composition metrics in the largest cohort to date.

More about this publication

Journal of the National Cancer Institute

Volume 117
Issue nr. 6
Pages 1245-1252
Publication date 01-06-2025

Full text links

Publisher website (DOI) 10.1093/jnci/djaf039
Europe PubMed Central 39980388
Pubmed 39980388

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.